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Abstract  
Background  
COVID-19 pandemic has created an extreme pressure on the global healthcare services. Fast, reliable and early clinical assessment of 
the severity of the disease can help in allocating and prioritizing resources to reduce mortality.  
Methods 
In order to study the important blood biomarkers for predicting disease mortality, a retrospective study was conducted on 375 COVID-
19 positive patients admitted to Tongji Hospital (China) from January 10 to February 18, 2020. Demographic and clinical characteristics, 
and patient outcomes were investigated using machine learning tools to identify key biomarkers to predict the mortality of individual 
patient. A nomogram was developed for predicting the mortality risk among COVID-19 patients.  
Results 
Lactate dehydrogenase, neutrophils (%), lymphocyte (%), high sensitive C-reactive protein, and age - acquired at hospital admission 
were identified as key predictors of death by multi-tree XGBoost model. The area under curve (AUC) of the nomogram for the derivation 
and validation cohort were 0.961 and 0.991, respectively. An integrated score (LNLCA) was calculated with the corresponding death 
probability.  COVID-19 patients were divided into three subgroups: low-, moderate- and high-risk groups using LNLCA cut-off values 
of 10.4 and 12.65 with the death probability less than 5%, 5% to 50%, and above 50%, respectively. 
Conclusions  
The prognostic model, nomogram and LNLCA score can help in early detection of high mortality risk of COVID-19 patients, which 
will help doctors to improve the management of patient stratification. 
Keywords: Machine Learning, Prognostic Model, Early Warning Tool, Predicting Mortality Risk, COVID-19. 
INTRODUCTION  
The novel coronavirus disease (COVID-19) spread rapidly 
throughout the world from Wuhan (Hubei, China) since 
December 2019 [1-5]. Since the outbreak, the number of 
reported cases has surpassed 12 million with more than 550 
thousand deaths worldwide as of 12 July 2020 [6]. The 
COVID-19 disease is caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), which is a member 
of the coronavirus family. On 11 March 2020, COVID-19 was 
declared as a pandemic by the World Health Organization 
(WHO) [7]. Due to the pandemic, hospital capacity is being 
exceeded  in many places and face issues in terms of limited 
medical staff, personal protective equipment, life-support 
equipment and others [8, 9]. Symptoms of COVID-19 are non-
specific, and infected individuals may develop fever (83-
99%), cough (59-82%), loss of appetite (40-84%), fatigue (44-
70%), shortness of breath (31-40%), coughing up sputum (28-
33%) or muscle aches (11-35%) [10]. The disease can further 
progress into a severe pneumonia, acute respiratory distress 
syndrome (ARDS), myocardial injury, sepsis, septic shock, 
and even death [11]. Though most COVID-19 patients have a 
mild illness, there are some patients who show rapid 
deterioration (particularly within 7–14 days) from the onset of 
symptoms into severe COVID-19 with or without ARDS [12, 
13]. Current epidemiological data suggest that the mortality 
rate of patients with severe COVID-19 is higher than that of 
patients with non-severe COVID-19 [14, 15]. It has been 
reported that 26.1-32.0% of patient infected with COVID-19 
are prone to progressing critical illness [16]. Recent studies 
have confirmed a high fatality rate of 61.5% for patients in 
critical cases, which increases with age and other medical 
comorbidities [16]. 
A large cohort study from 2449 patients has reported that 
during this pandemic healthcare system can be overwhelmed  
by hospitalization (20-31%) and intensive care unit (ICU) 
admission rates (4.9-11.5%) [17]. This can be avoided by 
prioritizing hospital treatment for patients at high risk of 
deterioration and death, and treating low-risk patients in 
ambulatory environments, or by home-based self-quarantine. 
An effective tool is required to predict the disease trajectory to 
allocate resources efficiently and also improve the patient’s 
condition.  Understanding the great potential of this approach, 
it is important to identify key patient variables that can help to 
predict the course of the disease at diagnosis. In other words, 
early identification of patients at high risk for progression to 
severe COVID-19 will help in efficient utilization of 
healthcare resources via patient prioritization to reduce the 
mortality rate. 
Several researches indicate that biomarkers can help to 
classify COVID-19 patients with elevated risk of serious 
disease and mortality by providing crucial information 
regarding the patients’ health status. Al Youha et al. [18] 
proposed a prognostic model called the Kuwait Progression 
Indicator (KPI) Score for predicting progression of severity in 
COVID-19. The KPI model was based on quantifiable 
laboratory readings unlike other self-reported symptoms and 
other subjective parameters based scoring systems. The KPI 
score categorizes patients to low risk if the score goes below -
7 and high risk if the score goes above 16, however, the 
progression risk in the intermediate group (for patients scores 
within -6 to 15) deemed by the authors as uncertain. This 
intermediate category however exists with many prognostic 
systems. Weng et al. [19] reported an early prediction score 
called ANDC to predict mortality risk for COVID-19 patients 
using 301 adult patients’ data. LASSO regression has 
identified age, neutrophil-to-lymphocyte ratio (NLR), D-
dimer, and C-reactive protein recorded during admission as 
mortality predictors for COVID-19 patients  [19]. They have 
developed a nomogram demonstrating good performance and 
also derived an integrated score, ANDC, with its 
corresponding death probability. They have also developed 
cutoff ANDC values to classify COVID-19 patients into three 
groups: Low, Moderate and High-risk groups. The death 
probability were 5%, 5% to 50% and more than 50% in the 
low-, moderate- and high-risk group, respectively. Using a 
cohort of 444 patients, Xie et al. [20] proposed a prognostic 
model using lactate dehydrogenase, lymphocyte count,  age, 
and SpO2 as key-predictors of COVID-19 related death. The 
model showed good discrimination for internal and external 
validation with C-statistics of 0.89 and 0.98 respectively. 
(c=0ꞏ98) validation. Even though the model shows promising 
performance for internal calibration, however, external 
validation showed over and under-prediction for low-risk and 
high-risk patients respectively.  
Yan et al. [21] reported a machine learning approach to 
select three biomarkers (lactic dehydrogenase (LDH), 
lymphocyte and high-sensitivity C-reactive protein (hs-CRP)) 
and using them to predict individual patients mortality, 10 
days ahead with more than 90 percent accuracy. In particular, 
high levels of LDH alone have been found to play a crucial 
role in identifying the vast majority of cases, which require 
immediate medical attention. However, there is no scoring 
system reported in this work, which can help the clinicians to 
identify the patients under risk quantitatively.  
Another clinical study on 82 COVID-19 patients showed 
that respiratory, cardiac, hemorrhage, hepatic, and renal injury 
had caused the death of 100%, 89%, 80.5%, 78.0%, and 31.7% 
patients respectively. Most of the patients had increased CRP 
(100%) and D-dimer (97.1%) [22]. The value of D-dimer as a 
prognostic factor was also shown to significantly increase 
odds of death if the amount is greater than 1 μg mL−1 upon 
admission  [23, 24]. 
Although several predictive prognostic models are 
proposed for the early detection of individuals at high risk of 
COVID-19 mortality, a major gap remains in the design of 
state-of-the-art interpretable machine learning based 
algorithms and high performance quantitative scoring system 
to classify the most selective predictive biomarkers of patient 
death. Identifying and prioritizing those at severe risks is 
important for both resource planning and treatment therapy. 
Moreover, the high risk patients should be possible to 
continuously monitored using a reliable scoring tool during 
their hospital stay-time.  Likewise, reducing patient admission 
with very low risk of complications that can be handled safely 
by self-quarantine will help to minimize the pressure on 
healthcare facilities. 
Therefore, using state-of-the-art machine learning 
algorithm, an early prediction scoring system was developed 
and also implemented to classify the most discriminatory 
biomarkers of patient mortality. The problem was initially 
introduced as a classification problem for determining the 
most appropriate biomarkers at the end of the test period with 
the aid of corresponding survival or death outcomes. The top 
ranked features with the best classification performance were 
used to develop a multivariable logistic regression-based 
nomogram and validated for the prognosis of death and 
survival. The findings obtained through this study provides a 
simple, easy-to-use and reliable algorithm for the prognosis of 
high-risk individuals and possess potential for clinical 
application. 
 
METHODLOGY  
A. HUMAN SUBJECTS AND STUDY DESIGN 
Blood samples collected between 10 January and 18 
February, 2020 from 375 patients in Wuhan, China were 
retrospectively analyzed to identify reliable and relevant 
markers of mortality risk. Medical records were collected 
using standard case report forms, which included information 
on epidemiological, demographic, clinical, laboratory and 
mortality outcomes. Yan et al. [21] has published the dataset 
along with the article and the original study was approved by 
the Tongji Hospital Ethics Committee. Patients’ exclusion 
criteria for the study were: Age (<18 years), pregnant, breast-
feeding and missing data (>20%). Out of 375 patients, 187 
(49.9%) had fever while cough, fatigue, dyspnea, chest 
distress and muscular soreness were present in 52 (13.9%), 14 
(3.7%), 8 (2.1%), 7 (1.9%) and 2 (0.5%) patients respectively.  
 
B. STATISTICAL ANALYSIS 
Stata/MP 13.0 software was used for conducting the statistical 
analysis. Gender variation was described using number and 
percentage. Continuous variables, age and other biomarkers 
were reported with the number of missing data, median, mean, 
and quartiles (Q1, Q3) for each biomarkers in death, and 
survival groups. Wilcoxon tests were conducted for all 
continuous variable while the chi-squared test for univariate 
analysis such as gender. Statistically significant difference was 
defined as a P-value <0.05. There were 76 biomarkers present 
in the original dataset however 14 biomarkers using two-
different algorithms were identified as promising and are 
summarized in Table 1. These 14 biomarkers selected included 
lactate dehydrogenase (LDH), neutrophils (%), lymphocyte 
(%), high sensitivity C-reactive protein (hs CRP), serum 
sodium,  eosinophil (%), serum chloride, monocyte (%), 
international normalized ratio (INR), activated partial 
thromboplastin time (APTT), high sensitivity cardiac troponin 
I, brain natriuretic peptide precursor (NT-proBNP), albumin, 
and mean corpuscular hemoglobin concentration (MCHC).  
Table 1: Statistical Analysis of the Characteristic of the subjects’ data 
Item  Survived Death  Total Method  Statistic P value 
Gender 
 Male (%) 
 Female (%) 
 
98(49%) 
103(51%) 
  
126(72%) 
48(28%) 
  
224(60%) 
151(40%) 
 Chi-
square 
test 
X2=21.70 <0.00001 
       
Age 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
201(0) 
50.2±15 
51 
37, 62 
18, 88 
 
174(0) 
68.8±11.8 
69 
62.2, 77 
19, 95 
 
375(0) 
58.8±16.5 
62 
46, 70 
18, 95 
Rank-
sum test 
Z=-11 <0.0001 
       
Lactate dehydrogenase 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
193(8) 
271±102 
250 
203, 312 
119, 799 
 
 
163(11) 
642±341 
567 
428, 762 
188,1867 
 
 
356(19) 
441±305 
336 
239, 564 
119, 1867 
Rank-
sum test 
Z=-13.18 <0.0001 
       
Neutrophils (%) 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
194(7) 
65.7±13.8 
66.2 
56.5, 75.4 
1.7, 95.1 
 
162(12) 
87±9.86 
89.5 
83.2, 93.7 
18.2, 98.7 
 
356(19) 
75.4±16.1 
77.5 
64.3, 89.2 
1.7, 98.7 
Rank-
sum test 
Z=-12.88 <0.0001 
       
Lymphocyte (%) 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
194(7) 
24.8±11.4 
23.8 
16.6, 33.5 
4.1, 60 
 
162(12) 
7.6±6.22 
5.8 
3.3, 10.1 
0, 44.3 
 
356(19) 
17±12.7 
14.4 
6.1, 25.2 
0, 60 
Rank-
sum test 
Z=11.97 <0.0001 
       
High sensitivity C-
reactive protein 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
194(7) 
36±44 
19 
4, 50 
0, 237 
 
 
159(15) 
127±75.5 
114 
62, 179 
4, 320 
 
 
353(22) 
77±75.4 
53 
12, 118 
0, 320 
Rank-
sum test 
Z=-11.93 <0.0001 
       
Serum sodium 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 
193(8) 
138.9±3.38 
139.2 
136.6, 141 
125, 146.4 
 
161(13) 
139.9±8.37 
138.9 
135.8, 143 
115.4, 179 
 
354(21) 
139.3±6.18 
139 
136.3, 142 
115.4, 179 
Rank-
sum test 
Z=-1.57 0.12 
 Min, Max 
       
Eosinophil (%) 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
194(7) 
0.7±.941 
0.3 
0, 1.1 
0, 6.40 
 
162(12) 
0.11±0.38 
0.00 
0.0,  0.0 
0, 3.70 
 
356(19) 
0.44±.79 
0.00 
0.00,0.53 
0.00, 6.40 
Rank-
sum test 
Z=6.63 <0.0001 
       
Serum chloride 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
193(8) 
100.8±3.8 
101.3 
98.8, 103.3 
85.6, 109.1 
 
161(13) 
101.5±8.56 
100.6 
97.1, 105.5 
71.5, 140 
 
354(21) 
101.1±6.42 
101.1 
97.9, 103.9 
71.5, 140 
Rank-
sum test 
Z=-0.65 0.52 
       
Monocyte (%) 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
194(7) 
8.4±3.15 
8.2 
6.6, 10.1 
0.7, 15.8 
 
152(12) 
5.1±4.31 
4 
2.4, 6.3 
0.3, 35.2 
 
356(19) 
6.9±4.08 
6.8 
3.8, 9.2 
0.3, 35.2 
Rank-
sum test 
Z=8.42 <0.0001 
       
International standard 
ratio 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
189(12) 
1.055±.086 
1.040 
1, 1.1 
0.84, 1.33 
 
 
163(11) 
1.37(1.01) 
1.22 
1.1, 1.37 
0.88, 13.48 
 
 
352(23) 
1.2±.709 
1.1 
1, 1.2 
0.8, 13.5 
Rank-
sum test 
Z=-9.4 <0.0001 
       
Activation of partial 
thromboplastin time 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
165(36) 
40.1±5.7 
39.9 
35.9, 43.5 
22, 56.9 
 
 
133(41) 
41.9±11.4 
39.4 
35, 45.4 
25.3,137 
 
 
298(77) 
41±8.7 
40 
36, 44 
22, 137 
Rank-
sum test 
Z=-1.2 0.23 
       
Hypersensitive cardiac 
troponin I 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
141(60) 
12±53.3 
3 
2, 7 
2, 617 
 
 
146(28) 
1391±5748 
41 
15, 271 
2, 50000 
 
 
287(88) 
714±414 
11 
3, 50 
2, 50000 
Rank-
sum test 
Z=-5.82 <0.0001 
       
Brain natriuretic 
peptide precursor (NT-
proBNP) 
 N(missing) 
 Mean ± SD 
 Median 
 
 
 
128(73) 
1039±6620 
65 
 
 
 
139(35) 
2806±5906 
827 
 
 
267(108) 
1959±6308 
271 
68, 935 
Rank-
sum test 
Z=-3.87 <0.0001 
 Q1, Q3 
 Min, Max 
23, 178 
5, 70000 
362, 2402 
24, 45850 
5,70000 
       
Albumin 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
193(8) 
37.1±4.53 
37.4 
34.2, 40.2 
22.6, 48.6 
 
163(11) 
30.3±4.22 
30.1 
27.6, 33 
18.5, 40.9 
 
356(19) 
34±5.57 
34.2 
29.9, 38.3 
18.5, 48.6 
Rank-
sum test 
Z=10.64 <0.0001 
       
Mean corpuscular 
hemoglobin 
concentration 
 N(missing) 
 Mean ± SD 
 Median 
 Q1, Q3 
 Min, Max 
 
 
 
194(7) 
343±13.9 
344 
335, 351 
306,416 
 
 
162(12) 
346±18.7 
346 
337,354 
299,488 
 
 
356(19) 
345±16.3 
345 
336, 352 
299, 488 
Rank-
sum test 
Z=-2.27 0.023 
       
Outcome (%) 201(54%) 174(46%) 375    
 
Figure 1: Patients’ outcome tree with the initial condition of the patients in admission. 
 
C. FEATURE RANKING 
Even though multiple blood sample data of the patients 
were available, only the data from the first sample were used 
as inputs for model training and validation to identify the key 
predictors of the disease severity. The model also helps in 
distinguishing patients that require immediate medical 
assistance. Research using clinically captured data often 
suffers from missing data challenge leading to either bias 
introduction or negative impact on analytical outcomes. 
Simple approach to handle this challenge is deleting the 
respective rows of data from further analysis. This simple 
approach is not very useful as it leads to loss of valuable 
information that would have been beneficial in the analysis 
and also can lead to biased estimates [25].  
375 patients with outcome 
of survival and death
Survived- 185 Died-12
General-197 Severe-27 Critical-151
Survived- 13 Died-14 Survived- 3 Died-148
Multiple imputation using chained equations (MICE) data 
imputation technique is the most popular technique for clinical 
data imputation. MICE technique uses multiple regression 
models to predict the missing data depending on other 
variables in the dataset. In this technique, each of the missing 
variables is modelled depending on the datatype. Binary 
variables are predicted using logistic regression while 
continuous variables were predicted using predictive mean 
matching [25].   
In this study two different data imputation techniques are 
compared. In the first technique [21],  missing data were 
padded by ‘−1’ and normalized by ‘Z-score’ whereas in the 
second technique, missing data were imputed using MICE 
technique and normalized using ‘Z-score’.  
Each of the 76 parameters were assessed to take decisions 
and identify the top-14 biomarkers in addition to age and 
gender, to obtain the top-ranked biomarkers as mortality 
predictors. Two different sets (Top 10 features) were identified 
using Multi-Tree Extreme Gradient Boost (XGBoost) 
technique [26], according to their importance from the 
imputed and normalized data using two imputation techniques 
mentioned earlier. The importance of each individual feature 
in XGBoost is from its accumulated use in each decision step 
in trees. The approach is extremely useful when dealing with 
clinical parameters [21]. Initially, default settings of XGBoost 
was used, i.e. maximum depth = 4, learning rate = 0.2, tree 
estimators = 150, regularization parameter α = 1 and 
'subsample' and 'colsample bytree' both set to 0.9 to avoid 
overfitting for cases with many features and limited sample 
size [21].   
 
D. DEVELOPMENT AND VALIDATION OF THE 
LOGISTIC REGRESSION MODEL IN 
CLASSIFYING THE OUTCOME 
This study uses a supervised logistic regression classifier 
[27] as the predictor model. Logistic regression is a common 
model used in medical statistics and is a statistical learning 
technique categorized in supervised’ machine learning (ML) 
methods dedicated to classification tasks [28]. The logistic 
function is a sigmoid function and shrinks real value 
continuous inputs into a probability. They also  make the 
independent values more resistant to deviations from 
normality and thus more consistent coefficients [28] . 
ROC curves using testing data were constructed to 
calculate the area under curve (AUC) for single predictors 
separately and also combination of them. In order to evaluate 
the performance of different top ranked features in classifying 
death and survival cases. The logistic regression classifier was 
evaluated for different combinations of features as input to the 
model. The trained algorithms were validated using 5-fold 
cross-validation (80% data were used for training and 
validation while remaining 20% data were used for testing and 
this is repeated 5-times). The performance of different models 
were evaluated using several performances metrics including 
sensitivity, specificity, positive likelihood ratio (PLR) and 
negative likelihood ratio (NLR) using testing dataset. Per-class 
values were computed over the overall confusion matrix that 
accumulates all test (unseen) fold results of the 5-fold cross-
validation. 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦௖௟௔௦௦೔ ൌ
𝑇𝑃௖௟௔௦௦೔
𝑇𝑃௖௟௔௦௦೔ ൅ 𝐹𝑁௖௟௔௦௦೔
 (1) 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦௖௟௔௦௦_௜ ൌ 𝑇𝑁௖௟௔௦௦_௜𝑇𝑁௖௟௔௦௦_௜ ൅ 𝐹𝑃௖௟௔௦௦_௜      (2) 
𝑃𝐿𝑅௖௟௔௦௦_௜ ൌ
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦௖௟௔௦௦೔
1 െ 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦௖௟௔௦௦_௜      (3) 
𝑁𝐿𝑅௖௟௔௦௦_௜ ൌ
1 െ  𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦௖௟௔௦௦೔
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦௖௟௔௦௦_௜       (4) 
where 𝑐𝑙𝑎𝑠𝑠௜ ൌ 𝑆𝑢𝑣𝑖𝑣𝑎𝑙 𝑎𝑛𝑑 𝐷𝑒𝑎𝑡ℎ.     
E. DEVELOPMENT AND VALIDATION OF LOGISTIC 
REGRESSION-BASED NOMOGRAM IN THE 
OUTCOME PREDICTION 
A diagnosis nomogram was constructed by Alexander 
Zlotnik's Nomolog [29], based on multivariate logistic 
regression analysis, using Stata/MP software version 13.0. 
Logistic (logit) regression estimates the parameter in the form 
of a binary regression. Logistic regression works with 
probability, odds and regression. In the binary logistic model, 
there is an outcome/indicator variable which has two possible 
values. The outcome variable is a dependent variable which is 
typically labeled as ‘0’ and ‘1’ and ‘0’ represent survival and 
‘1’ represents death in this case. The odds are the ratio of the 
probability of an event happening to the probability of not 
happening. Although the probability can vary between 0 and 
1, the odds can vary between 0 and . In logistic regression, 
the logarithm of odds is a linear combination of one or more 
independent variables ("predictors") which can be a binary 
variable (e.g., gender) and continuous variable (e.g., age). The 
log-odds can be termed as linear prediction (LP) and can be 
related to the probability of a particular outcome. The 
following equations were used to create relationship between 
death probability and the key-predictors using logistic 
regression: 
 𝑜𝑑𝑑𝑠 ൌ  ௉ଵି௉                        (5) 
𝐿𝑃 ൌ  lnሺ𝑜𝑑𝑑𝑠ሻ ൌ ln ൬ 𝑃1 െ 𝑃൰
ൌ 𝑏଴ ൅ 𝑏ଵ𝑥ଵ ൅ 𝑏ଶ𝑥ଶ ൅ ⋯ ൅ 𝑏௡𝑥௡  ሺ6ሻ 
௉
ଵି௉ ൌ 𝑒௕బା௕భ௫భା௕మ௫మା⋯ା௕೙௫೙ ൌ 𝑒௅௉  (7) 
 
𝑃 ൌ  𝑒
௅௉
1 ൅ 𝑒௅௉ ൌ  
1
1 ൅ 𝑒ି௅௉  ሺ8ሻ 
 
The top-ranked features (independent variables) showing 
best AUC was used for creating the logistic regression based 
nomogram. The entire dataset was divided into training (70%) 
and validation (30%) sets. Calibration curves for internal (with 
development set) and external (with validation set) validation 
were plotted to compare predicted and actual death probability 
of patients with COVID-19. Decision curve analysis (DCA) 
was carried out to identify the threshold values in which 
nomograms were clinically useful, using Stata software. 
 
F. DEVELOPMENT AND VALIDATION OF EARLY 
WARNING SCORE 
 The parameters were drawn as a numerated horizontal axis 
scale and the values for the patient are put on the numerated 
scale. A vertical line was drawn down from the different 
parameter numerated arranged scales downward to a score 
axis. All five scores on the score axis were added to make a 
total score and this was linked to a death probability. It can be 
noted that according to the nomogram, higher score 
corresponds to a higher death probability. The model was 
designed using the initial blood sample of the patients. 
However, it can be applied to the biomarkers collected in later 
during the hospital stay period of the patients to predict death 
probability longitudinally using the LNLCA score.  
RESULTS  
A. DEMOGRAPHIC  CHARACTERISTICS, CLINICAL 
CHARACTERISTICS, AND CLINICAL OUTCOMES 
Of the 375 patients, 174 (46.4%) died, while 201 (53.6%) 
patients recovered from COVID-19 and were discharged from 
hospital. Figure 1 summarizes the outcome of patients based 
on their initial conditions: general (197), severe (27) and 
critical (151). The minimal, maximal and median follow-up 
times (from hospital admission to death or discharge) for all 
375 patients are 0 days, 35 days and 12 days, respectively.  
Table 1 summarizes the demographic characteristics, 
clinical characteristics, and clinical outcomes of the subjects 
in the death and survival groups. There were 142 (37.9%) 
patients, who were Wuhan residents, 2 (0.5%) had contact 
with confirmed or suspected patients, 24 (6.4%) were from 
familial cluster, 7 (1.9%) were health workers, 2 (0.5%) had 
contact with Huanan Seafood Market and 198 (52.5%) had no 
contact history.  
224 (59.7%) patients were male while 151 (40.3%) were 
female and the mean age of the patients was 58.83 years with 
a standard deviation of 16.46 years. Even though 76 
demographic, laboratory, and clinical characteristics were 
available in the dataset, 14 biomarkers and two demographic 
variables were identified using feature ranking. Using two 
different feature ranking techniques, two different top-10 
features were identified as most contributing features (Figure 
2). Some features are found common to both the techniques 
resulting in 15 different features contributing most for early 
prediction of death.  
The detailed description of 16 characteristics are listed in 
Table 1. It was found that gender, age, LDH, neutrophils (%), 
lymphocyte (%), hs-CRP, eosinophil (%), monocyte (%), INR, 
high sensitivity cardiac troponin I, NT-proBNP and albumin 
had statistically significant differences between the groups 
groups (P < 0.05), whereas serum sodium, serum chloride, 
APTT, MCHC variables were not significantly different (P > 
0.05) among the two groups. Out of these 16 characteristics, 
12 characteristics were observed statistically significant. 
Therefore, it was important to check the most useful variables 
for the early prediction of death.  
 
B. UNIVARIATE LOGISTIC REGRESSION ANALYSIS 
OF VARIABLES SIGNIFICANTLY ASSOCIATED 
WITH DEATH 
To determine the independent variables associated with 
death, univariate logistic regression analysis was performed 
with Top-1, Top-2, and up to Top-10 features identified using 
two different techniques. It is clear from the Figure 3 that Top 
ranked 5 features produced highest AUC of 0.97 for data 
imputed using MICE algorithm while Top-ranked 3 features  
produced highest AUC of 0.95 for the data imputed using -1 
(Figure 3).  Table 2 shows the overall accuracies and weighted 
average performance for other matrices for different models 
using Top 1 to 10 features for 5-fold cross-validation using the 
logistic regression classifier along with the confusion matrices 
for each case.  
 
 
Figure 2: Comparison of the top-ranked 10 features identified using Multi-Tree XGBoost algorithm from data imputed using 
MICE (left) and (-1) (right). 
 
Figure 3: Comparison of the receive operating characteristic (ROC) plots for top-ranked 1 up to 10 features using the data 
imputation using MICE (left) and (-1) (right) while feature selection and classification techniques were same. 
Table 2: Comparison of the average performance matrix and confusion matrix from five-fold cross-validation for top1 to 10 
features using data imputation using (-1) (A) and mice (B). 
 
A 
Weighted Average (95% confidence interval) Confusion Matrix 
Sensitivity Specificity PLR NLR Death Survived 
TP FN FP TN 
Top 1 feature 87±3.92 87.4±3.01 7.4±4.1 0.15±0.1 142 32 14 187 
Top 2 features 88.04±3.13 88±3.5 8.1±5.1 0.14±0.08 148 26 17 184 
Top 3 features 90±3.8 88.9±3.78 9.3±6.9 0.12±0.09 155 19 19 182 
Top 4 features 90.5±3.92 90.7±3.72 11.8±10.1 0.10±0.09 157 17 18 183 
Top 5 features 90.1±3.6 90.03±3.5 10.5±7.9 0.11±0.086 155 19 18 183 
Top 6 features 90.08±2.7 90±2.4 9.63±5.1 0.11±0.06 154 20 19 182 
Top 7 features 89.8±2.3 90.16±3.4 10.5±7.5 0.12±0.05 156 18 21 180 
Top 8 features 89.3±3.6 89.1±3 8.96±5.5 0.12±0.08 155 19 21 180 
Top 9 features 89.6±3.2 88.9±3.5 9.06±6.2 0.11±0.07 153 21 20 181 
Top 10 features 89.01±3.3 89.01±4 9.46±7.3 0.13±0.083 154 20 21 180 
 
  
        B 
 
Weighted Average (95% confidence interval) Confusion Matrix 
Sensitivity Specificity PLR NLR Death Survived 
TP FN FP TN 
Top 1 feature 88.2±7.4 87.6±3.5 7.91±5.6 0.13±0.17 143 31 13 188 
Top 2 features 87.7±4.4 87.01±3.5 7.37±4.6 0.14±0.11 145 29 17 184 
Top 3 features 87.1±3.5 87±4.1 7.53±5.2 0.15±0.09 148 26 22 179 
Top 4 features 89.2±2.8 89±3.2 8.93±5.6 0.12±0.07 155 19 22 179 
Top 5 features 92±2.6 92±3 13.52±10.6 0.09±0.06 160 14 16 185 
Top 6 features 92.3±2.45 92±4.1 15.86±16.5 0.085±0.06 162 12 17 184 
Top 7 features 90.2±5 90.6±3.5 11.37±9.3 0.11±0.12 158 16 22 179 
Top 8 features 89.9±4.8 90.2±3.8 11.02±9.3 0.11±0.11 158 16 23 178 
Top 9 features 89.2±2.8 89.03±3.2 8.97±5.6 0.12±0.07 155 19 22 179 
Top 10 features 88±3.4 89.6±3.7 9.82±7.5 0.14±0.08 156 18 23 178 
Top-ranked 5 features using MICE data imputation showed 
better performance than the Top-ranked 4 features for the data 
imputed by (-1). Therefore, in the rest of the study, 5 Top-
ranked MICE imputed independent variables: Lactate 
dehydrogenase, Neutrophils (%), Lymphocyte (%), high 
sensitivity C-reactive protein and Age (in short LNLCA) were 
used for nomogram creation and scoring technique 
development and validation.   
 
C. DEVELOPMENT AND EVALUATION OF 
NOMOGRAM IN PREDICTING DEATH 
A multivariate logistic regression based nomogram for 
predicting early COVID-19 mortality was built using top-
ranked five biomarkers that were found important both 
statistically and using ML based classifier (as shown in Table 
1, 2 and Figure 3). The relationship between linear prediction 
of death and these biomarkers was evaluated using 
multivariable logistic regression which was reported in Table 
3.  Regression coefficient, z-value, standard error and its 
statistical significance along with 95% confidence interval 
were shown in Table 3. Z-value is the ratio of regression 
coefficient and its standard error. Typically z-value indicates 
the strong and weak contributors in logistic regression. The 
higher z-values (either positive/negative) represent a strong 
contributor while values close to zero represent a weak 
contributor. Therefore, out of 5 variables neutrophils (%) is not 
very strong predictor while age and Lactate dehydrogenase are 
strong contributor. A null hypothesis of particular regression 
coefficient can determine the p-value to relate the significance 
of a particular X-variable in relationship to the Y-variable. The 
X-variables for which p is less than 0.05, have significant 
relationship to Y-variables. This is also reflecting that the 
neutrophils (%) is weakly related to Y-variable. However, the 
logistic regression classifier shows that 5 variables 
outperforms than 4 variables. Therefore, no variable was 
discarded out of these 5-variables in developing the 
nomogram.  
According to Figure 4, the calibration plot graphed 
closely toward the diagonal line both for internal and external 
validation which were indicative of the reliable model. It is 
evident from figure 5 that the net benefit of every single 
predictor model is positive until threshold of 0.85. This 
indicates that all of them contributed to the prediction of 
outcomes. Interestingly, the full model demonstrated the best 
performance which also confirmed the need to combine five 
predictors in the model.  
As shown in Figure 6, the nomogram is comprised of 8 
rows while row 1-5 are representing independent variables. 
For each variable, an assigned score was obtained by drawing 
a downward vertical line from the value on the variable axis to 
the “points” axis using COVID-19 patient data. The points of 
the five variables corresponds to score (row 6) and the scores 
were added up to the Total score, as shown in row 8.  Then a 
line could be drawn from the “Total Score” axis to the “Prob” 
axis (row 7) to determine the death probability of COVID-19 
patients. However, it is useful to derive the mathematical 
equations explaining the total score, linear prediction and 
death probability based on which the LNLCA score is 
calculated:  
Total points = 0.0053375*lactate dehydrogenase (/L) - 
0.02474*(Neutrophils (%)-98.7) - 
0.12333*(Lymphocyte (%) - 60) + 0.0084375*hsCRP 
(mg/L) + 0.055844*age (years)          (9) 
Linear prediction ൌ െ3.662636 ൅  0.0735038 ൈ
age ሺyearsሻ ൅ 0.0110451 ൈ hsCRP ቀ୫୥୐ ቁ െ
0.1624422 ൈ lymphocyteሺ%ሻ െ 0.0327053 ൈ
neutrophilsሺ%ሻ ൅  0.0070514 ൈ
lactate dehydrogenaseሺ୳୐ሻ                    (10)  
Death probability=1/ (1+exp (-Linear Prediction))   (11) 
The corresponding probability of death for a given 
LNLCA score was determined from the model and is listed in 
Table 4. In particular, LNLCA score cut-off values of 10.4 and 
12.65 were correspond to 5% and 50% of death probability, 
thus these values can be used to stratify COVID-19 patients 
into three groups: Low, moderate and high-risk groups. The 
death probability were less than 5%, between 5% and 50 % 
and more than 50 % for low risk group (LNLCA < 10.4), 
moderate risk group (10.4 ≤ LNLCA ≤ 12.65) and high risk 
group (LNLCA >12.65) respectively. 
 
Table 3: The logistic regression analysis to construct the nomogram for death prediction. 
Outcome Coef. Std. Err. z P>|z| [95% conf.  Interval] 
Lactate dehydrogenase .0070514 .0017099 4.12 0.000 .0037001 .0104027 
Neutrophils -.0327053 .0568836 -0.57 0.565 -.1441951 .0787845 
Lymphocyte -.1624422 .0806231 -2.01 0.044 -.3204607 -.0044238 
High Sensitivity CRP .0110451 .0043462 2.54 .011 .0025267 .0195635 
Age .0735038 .0185211 3.97 0.000 .0372032 .1098045 
_cons -3.662636 5.65169 -0.65 0.517 -14.73975 7.414473 
 
 
Figure 4: Calibration plot comparing predicted and actual death probability of patients with COVID-19: (A) represents the 
internal validation and (B) represents the external validation. 
 
Figure 5: Decision curves analysis comparing different models to predict the death probability of patients with COVID-19. The 
net benefit balances the mortality risk and potential harm from unnecessary over-intervention for patients with COVID-19.  
 Figure 6:  Multivariate logistic regression-based Nomogram to predict the probability of death. Nomogram for prediction of 
death was created using the following five predictors: Lactate Dehydrogenase, Neutrophils (%), Lymphocytes (%), High Sensitive 
C-reactive protein, and age.  
 
Figure 7: An example nomogram based score to predict the probability of death of a COVID-19 patient from test set (9-days 
before the actual outcome).  
Table 4: LNLCA score from nomogram and corresponding 
death probability of COVID-19 patients  
Patient Group LNLCA Score Death probability 
 7.45 0.001 
Low 9.2 0.01 
 10.4 0.05 
 10.95 0.1 
 11.6 0.2 
Moderate 11.99 0.3 
 12.4 0.4 
 12.65 0.5 
 12.95 0.6 
 13.3 0.7 
 13.7 0.8 
High 14.3 0.9 
 14.8 0.95 
 16.2 0.99 
 17.85 0.999 
 
D. PERFORMANCE EVALUATION OF THE MODEL  
 
Figure 7 shows an example nomogram based scoring system 
for a COVID-19 patient with the variable values at admission. 
Individual score for each predictors were calculated and added 
to produce total score and death probability was calculated to 
80%. This can be done as early as 9 days before the death of 
the patient.  
Furthermore, we have categorized the patients from 
training and testing subgroups into three subgroups (low, 
moderate and high-risk) by associating actual outcome with 
the predicted outcome using the LNLCA score. For training 
set (Table 5), the proportions of death were 0% (0/83) for low 
risk group, 22.6% (12/53) for moderate risk group and 88.1% 
(111/126) for high risk group while for test set (Table 6), the 
proportions of death were 0% (0/41) for low risk group, 22.7% 
(5/22) for moderate risk group and 94% (3/50) for high risk 
group. It was found that the true death rates were significantly 
different (p<0.001) among the three subgroups. Therefore, this 
nomogram based scoring technique can be used to early 
predict patients’ outcome to categorize them into low, 
moderate and high-risk groups as shown in Table 4 and 
prioritize the moderate and high risk group patients. 
There were 52 patients in the test set who had an outcome 
of death after different duration of hospital stay. Some patients 
were hospitalized in very late stages while some other patients 
were admitted in the early stages. The minimum, maximum,  
 
Table 5: Association between different risk groups and actual outcome in the training cohort using Fisher exact probability test 
 
Risk category Outcome Overall Alive Death 
Low-risk 83 (100.0%) 0 (0%) 83 (100.0%) 
Moderate-risk 41 (77.36%) 12 (22.64%) 53 (100.0%) 
High-risk 15(11.9%) 111 (88.1%) 126 (100.0%) 
Overall 139 (53%) 123 (47%) 262 (100.0%) 
P-value among three group is less than 0.001 
P-value of Low-risk group vs Moderate-risk group is less than 0.001. 
P-value of Low-risk group vs High-risk group is less than 0.001.  
P-value of Moderate-risk group vs High-risk group is less than 0.001. 
 
 
Table 6: Association between different risk groups and actual outcome in the Testing cohort using Fisher exact probability test 
Risk category Outcome Overall Alive Death 
Low-risk 41 (100%) 0 (0%) 41 (100.0%) 
Moderate-risk 17 (77.27%) 5 (22.73%) 22 (100.0%) 
High-risk 3 (6%) 47 (94%) 50 (100.0%) 
Overall 61 (54%) 52 (46%) 113 (100.0%) 
P-value among three group is less than 0.001 
P-value of Low-risk group vs Moderate-risk group is 0.0037. 
P-value of Low-risk group vs High-risk group is less than 0.001. 
P-value of Moderate-risk group vs High-risk group is less than 0.001. 
 
 
Figure 8: Estimation of the prediction of the patients’ outcome for 52 test patients with death outcome. The model was trained 
on the data present at admission and multiple samples from a patient was used to predict the patient to be in high-risk group in 
the earliest time after admission. Note: ‘0’ denotes the death outcome event for each patient and vertical lines represent the time 
of admission with respect to death. Solid red line start from the earlies prediction time point of death prediction and the dotted 
line represent the delay between admission and death prediction by the model using the LNLCA model.  
 
mean (±standard deviation), and median of hospital admission 
to death for the test data set were 3.68, 760.92, 249.2±227.55 
and 172.79 hours respectively. Most patients out of the 375 
patients of the cohort had multiple blood samples taken 
throughout their hospital stay. LNLCA model based prediction 
score were calculated on the admission and also calculated for 
the next available samples and identified when the model is 
predicting the patient in high risk group in the earliest possible 
time after admission. Figure 8 shows the difference in hours 
between hospital admissions to the event of death and also 
shows when the model can predict the potential outcome with 
100% accuracy. It was evident from Figure 8 that the model 
can predict the outcome of 52 patients within several hours 
after admission for most of the patients. The minimum, 
maximum, mean (±standard deviation), and median of 
model’s high-risk prediction to death for the test data set were 
3.68, 756.11, 239.85±228.56 and 156.36 hours respectively. 
The model can even predict 31.5 days in advance for a patient 
about the outcome with a probability of 97%. This early 
prediction suggests that, where a patient’s condition 
deteriorates, the clinical route is able to give an early warning 
to clinicians several days in advance. 
 
DISCUSSION 
Current study investigated the relationship between the disease 
severity and the clinical data. Ten predictors were identified 
by Multi-Tree XGBoost algorithm as death probability 
predictors based on the data acquired at hospital admission 
time. Two different prediction models were compared while 
missing data were imputed using -1 and using MICE 
algorithm. Ten different classification model trained, validated 
and tested for Top 1 to 10 features using two different 
techniques. It was observed from the AUC and performance 
matrices that the MICE based technique outperforms other 
approach with an AUC = 0.97 was achieved for 5 Top-ranked 
features. Then, a logistic regression based nomogram was 
developed using these five variables. An integrated score 
(LNLCA) with corresponding likelihood of death was 
obtained for the early stratification of COVID-19 patients 
based on the severity prediction. This can help to effectively 
the use the healthcare facilities without overloading their 
capability. 
Age was identified as a key predictor of mortality in 
previous studies on Coronavirus family such as  SARS [30], 
Middle East respiratory syndrome (MERS) [31] and COVID-
19 [32]. This study has also concluded similar findings and 
this is because with the older age the immunosenescence 
and/or multiple medical conditions tend to make patients more 
prone to critical COVID-19 illness [19]. 
Yan et al. [16] showed that in patients with severe 
pulmonary interstitial disease, there is a significant increase of 
LDH and can be associated with indications for lung injury or 
idiopathic pulmonary fibrosis [33]. Consistent results from the 
previous research were also found in this study, in which 
critically ill patients with COVID-19 had elevated levels of 
LDH suggesting an increase in activity and severity of lung 
injury. LDH is an intracellular enzyme that leaks from 
damaged cells due to infection and viral replication leading to 
elevated levels in circulation. 
Recently, Liu et al. [34] proposed that increased 
Neutrophil-to-Lymphocyte Ratio (NLR) can aid in the early 
prediction of the severity of COVID-19 illness. Both 
neutrophils and lymphocytes are critical components of the 
immune system and play very important role in host defense 
and clearing infections. Lymphopenia, medical condition due 
to lower number of lymphocytes in the blood, is a typical 
feature in COVID-19 patients, and may be a key factor in 
disease severity and mortality [35]. In this study, we have used 
neutrophils and lymphocytes percentage and similar to the 
previous studies have found that lower percentage of these two 
quantities were associated with severe COVID-19 patients. 
According to previous research, patients with community-
acquired pneumonia have significant immune system 
activation and/or immune dysfunction leading to changes in 
these quantities [35]. In addition, on the event of 
immunosuppression and apoptosis of lymphocytes caused by 
specific anti-inflammatory cytokines, bone marrow circulates 
neutrophils [36], resulting in an increased NLR. However, in 
contrast to other models, it was observed in this study, both the 
parameters were small for high-risk patients.  
Lu et al. [37] stated that CRP tested upon admission may 
assist in predicting confirmed or suspected short-term 
mortality associated with COVID-19. CRP is an acute phase 
protein formed by hepatocytes caused by leukocyte-derived 
cytokines induced by infection, inflammation or tissue damage 
[38-40]. Similar findings were found in this study where 
increased CRP rates were measured at admission for the high 
mortality risk COVID-19 patients. This indicated that these 
patients developed a serious lung inflammation or possibly a 
secondary bacterial infection, and clinical antibiotic treatment 
might be appropriate for those patients  [21].  
Non-survivors in our study had low lymphocyte and 
neutrophil percentages, higher age, hsCRP and LDH than 
those of survivors. In addition to the dysregulation of the 
coagulation system and/ immune system, it can be seen that 
COVID-19 severity was significantly linked to the 
inflammatory response to the infection. This could lead to 
other worse medical consequences like ARDS, septic shock 
and coagulopathy etc. Therefore, this kind of prognostic model 
will aid in the development of a rational and personalized 
therapeutic plan for the patients with critical illness. 
Weng et al. [19] recently suggested that age, NLR, D-
dimer and CRP were individual key predictors correlated with 
death probability. These key-predictors were used to create a 
nomogram for death prediction due to COVID-19. In our 
research, the five key predictors recorded at admission were 
chosen by the XGBoost feature selection to create a nomogram 
based prognostic model that exhibits excellent calibration and 
discrimination in predicting death probability of COVID-19 
patients. It was also validated by an unseen validation cohort. 
Moreover, it was verified with multiple blood sample data 
collected from the patients during their hospital stay and the 
model holds valid for those cases as well. The AUC values for 
development and validation cohort showed a strong distinction 
of 0.961 and 0.991 respectively using the proposed nomogram, 
which is, to the best of our knowledge, outperforms any other 
nomogram based models for COVID-19 mortality prediction. 
In addition, this nomogram-derived LNLCA score offered a 
simple, easy-to-understand and interpretable early detection 
tool for stratifying the high-risk COVID-19 patients at 
admission and thereby assist their clinical management. 
COVID-19 patients were categorized into three risk groups 
with varying risk of death using LNLCA score measured and 
calculated at admission. Low-risk group cases could be 
isolated and treated in an isolation center while the moderate-
risk patients could be treated isolation ward in a specialized 
hospital. On the other hand, patients in high-risk group could 
be under close monitoring and should be moved to critical 
medical services or ICU for urgent treatment if required. 
This study has scope for further improvement, which will 
be carried out in the future work. Firstly, the study motivates 
the possibility of research on COVID-19 clinical data helping 
in early mortality prediction but the proposed machine 
learning method is purely data-driven and may vary if starting 
from different datasets. The model can be further improved 
with the help of a larger dataset. Secondly, the modelling 
principle adopted here is to have a minimal number of features 
for accurate predictions to avoid overfitting, which can be 
revised with several other models to identify any other sets of 
best features on a multi-center and multi-country data to 
produce a generalized model.  
CONCLUSION 
In summary, based on multiple risk factors (Lactate 
Dehydrogenase, Neutrophils (%), Lymphocytes (%), High 
Sensitive C-reactive protein, and age), our developed 
nomogram can predict the prognosis of patients with COVID-
19 with good discrimination and calibration. The model can 
predict the patient’s outcome far ahead of the day of primary 
clinical outcome with very high accuracy. Therefore, the 
application of LNLCA would help clinicians make an efficient 
and optimized patient stratification management plan without 
overloading the healthcare resources and also reduce the death 
with improved and planned response. The authors also plan to 
further improve the performance of the model with the help of 
larger dataset with multi-center and multi-country data. 
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